ATE465412T1 - Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen - Google Patents
Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungenInfo
- Publication number
- ATE465412T1 ATE465412T1 AT04818645T AT04818645T ATE465412T1 AT E465412 T1 ATE465412 T1 AT E465412T1 AT 04818645 T AT04818645 T AT 04818645T AT 04818645 T AT04818645 T AT 04818645T AT E465412 T1 ATE465412 T1 AT E465412T1
- Authority
- AT
- Austria
- Prior art keywords
- epilepsy
- immunosorb
- assessing
- blood tests
- paroxysmal cerebral
- Prior art date
Links
- 230000002490 cerebral effect Effects 0.000 title abstract 2
- 230000001314 paroxysmal effect Effects 0.000 title abstract 2
- 238000009534 blood test Methods 0.000 title 1
- 206010015037 epilepsy Diseases 0.000 abstract 5
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 230000002082 anti-convulsion Effects 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003547 immunosorbent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2857—Seizure disorders; Epilepsy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51767103P | 2003-11-06 | 2003-11-06 | |
| PCT/US2004/037088 WO2005046442A2 (en) | 2003-11-06 | 2004-11-08 | Immunosorbent tests for assessing paroxysmal cerebral discharges |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE465412T1 true ATE465412T1 (de) | 2010-05-15 |
Family
ID=34590180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04818645T ATE465412T1 (de) | 2003-11-06 | 2004-11-08 | Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7820398B2 (enExample) |
| EP (1) | EP1689288B1 (enExample) |
| JP (1) | JP4838140B2 (enExample) |
| CN (1) | CN1954211A (enExample) |
| AT (1) | ATE465412T1 (enExample) |
| AU (1) | AU2004288717A1 (enExample) |
| CA (1) | CA2585876A1 (enExample) |
| DE (1) | DE602004026767D1 (enExample) |
| EA (1) | EA200600920A1 (enExample) |
| WO (1) | WO2005046442A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6896872B2 (en) * | 2001-06-27 | 2005-05-24 | Svetlana A. Dambinova | Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke |
| US20060257943A1 (en) * | 2005-01-25 | 2006-11-16 | Cis Biotech, Inc. | Ischemic biomarkers and their use to predict adverse neurological events from surgery |
| CA2610833A1 (en) * | 2005-06-13 | 2006-12-21 | Cis Biotech, Inc. | Methods for diagnosing and treating cerebrovascular events based on nr2 peptides |
| US8536115B2 (en) | 2006-08-31 | 2013-09-17 | Centre For Addiction And Mental Health | Compositions and methods for modulating AMPA receptor-mediated excitotoxicity |
| WO2013102264A1 (en) * | 2012-01-04 | 2013-07-11 | Centre For Addiction And Mental Health | Compositions and methods for modulating ampa receptor-mediated excitotoxicity |
| US9759722B2 (en) * | 2012-12-17 | 2017-09-12 | Leukodx Ltd. | Systems and methods for determining a chemical state |
| WO2014097286A1 (en) | 2012-12-17 | 2014-06-26 | Leukodx, Ltd. | Systems and methods for determining a chemical state |
| US10610861B2 (en) | 2012-12-17 | 2020-04-07 | Accellix Ltd. | Systems, compositions and methods for detecting a biological condition |
| EP2863231A1 (en) * | 2013-10-17 | 2015-04-22 | Institut D'Investigaciones Biomédiques August Pi i Sunyer | Diagnostic method for detecting a GABA(A) related autoimmune disease and related subject-matter |
| US10194829B2 (en) | 2015-07-07 | 2019-02-05 | Q Bio, Inc. | Fast scanning based on magnetic resonance history |
| US9958521B2 (en) | 2015-07-07 | 2018-05-01 | Q Bio, Inc. | Field-invariant quantitative magnetic-resonance signatures |
| WO2017044919A1 (en) | 2015-09-12 | 2017-03-16 | Q Bio, Inc | Uniform-frequency records with obscured context |
| US10964412B2 (en) | 2015-10-20 | 2021-03-30 | Q Bio, Inc. | Population-based medical rules via anonymous sharing |
| US10222441B2 (en) | 2016-04-03 | 2019-03-05 | Q Bio, Inc. | Tensor field mapping |
| US10359486B2 (en) | 2016-04-03 | 2019-07-23 | Q Bio, Inc. | Rapid determination of a relaxation time |
| US11650195B2 (en) | 2017-02-03 | 2023-05-16 | Q Bio, Inc. | Iterative medical testing of biological samples |
| WO2018144044A1 (en) * | 2017-02-03 | 2018-08-09 | Q Bio, Inc. | lTERATIVE MEDICAL TESTING OF BIOLOGICAL SAMPLES |
| US10936180B2 (en) | 2017-03-16 | 2021-03-02 | Q Bio, Inc. | User interface for medical information |
| US11360166B2 (en) | 2019-02-15 | 2022-06-14 | Q Bio, Inc | Tensor field mapping with magnetostatic constraint |
| US11354586B2 (en) | 2019-02-15 | 2022-06-07 | Q Bio, Inc. | Model parameter determination using a predictive model |
| WO2020241443A1 (ja) | 2019-05-24 | 2020-12-03 | 富士レビオ株式会社 | サイログロブリンの測定方法及び測定試薬 |
| US11614509B2 (en) | 2019-09-27 | 2023-03-28 | Q Bio, Inc. | Maxwell parallel imaging |
| WO2021062154A1 (en) | 2019-09-27 | 2021-04-01 | Q Bio, Inc. | Maxwell parallel imaging |
| US12320880B2 (en) | 2019-09-27 | 2025-06-03 | Q Bio, Inc. | Maxwell parallel imaging |
| EP4036111A4 (en) | 2019-09-27 | 2023-10-25 | Fujirebio Inc. | HEPATITIS B VIRUS CORE ANTIGEN IMMUNOASSAY AND KIT THEREOF |
| CN115335700A (zh) | 2020-03-31 | 2022-11-11 | 富士瑞必欧株式会社 | 血中β淀粉样蛋白的免疫测定方法及用于该方法的试剂盒 |
| CN117616277A (zh) | 2021-08-06 | 2024-02-27 | 株式会社先端生命科学研究所 | 甲状腺球蛋白的免疫检测及用于其的试剂盒 |
| US11614508B1 (en) | 2021-10-25 | 2023-03-28 | Q Bio, Inc. | Sparse representation of measurements |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879289A (en) * | 1988-05-24 | 1989-11-07 | Marion Laboratories, Inc. | Method of ameliorating epileptic seizures |
| CA2071879C (en) * | 1989-10-27 | 2007-05-15 | Stephen F. Heinemann | Glutamate receptor compositions and methods |
| WO1993000586A1 (fr) | 1991-06-26 | 1993-01-07 | Obschestvo S Ogranichennoi Otvetstvennostju 'dies' | Immunoadsorbant utilise dans le diagnostic de l'epilepsie et d'un groupe a risque |
| WO1994006345A2 (en) | 1992-09-11 | 1994-03-31 | Dambinova Svetlana Alexandrovn | Immunosorbent for use in the diagnosis of neuro-psychological disorders, and use thereof |
| RU2112243C1 (ru) | 1995-11-29 | 1998-05-27 | Светлана Александровна Дамбинова | Набор "па-тест" для диагностики неврологических заболеваний |
| US6896872B2 (en) | 2001-06-27 | 2005-05-24 | Svetlana A. Dambinova | Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke |
| US20050233390A1 (en) * | 2003-04-09 | 2005-10-20 | Allen John W | Device including a proteinaceous factor, a recombinant proteinaceous factor, and a nucleotide sequence encoding the proteinaceous factor |
| US20060257943A1 (en) | 2005-01-25 | 2006-11-16 | Cis Biotech, Inc. | Ischemic biomarkers and their use to predict adverse neurological events from surgery |
-
2004
- 2004-11-08 EA EA200600920A patent/EA200600920A1/ru unknown
- 2004-11-08 EP EP04818645A patent/EP1689288B1/en not_active Expired - Lifetime
- 2004-11-08 CN CNA2004800399514A patent/CN1954211A/zh active Pending
- 2004-11-08 JP JP2006539691A patent/JP4838140B2/ja not_active Expired - Fee Related
- 2004-11-08 CA CA002585876A patent/CA2585876A1/en not_active Abandoned
- 2004-11-08 AU AU2004288717A patent/AU2004288717A1/en not_active Abandoned
- 2004-11-08 AT AT04818645T patent/ATE465412T1/de not_active IP Right Cessation
- 2004-11-08 DE DE602004026767T patent/DE602004026767D1/de not_active Expired - Lifetime
- 2004-11-08 WO PCT/US2004/037088 patent/WO2005046442A2/en not_active Ceased
- 2004-11-08 US US10/983,845 patent/US7820398B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005046442A2 (en) | 2005-05-26 |
| US7820398B2 (en) | 2010-10-26 |
| CN1954211A (zh) | 2007-04-25 |
| AU2004288717A2 (en) | 2005-05-26 |
| EA200600920A1 (ru) | 2007-04-27 |
| WO2005046442A3 (en) | 2006-12-07 |
| CA2585876A1 (en) | 2005-05-26 |
| JP4838140B2 (ja) | 2011-12-14 |
| DE602004026767D1 (de) | 2010-06-02 |
| US20050181466A1 (en) | 2005-08-18 |
| EP1689288A2 (en) | 2006-08-16 |
| AU2004288717A1 (en) | 2005-05-26 |
| JP2007517188A (ja) | 2007-06-28 |
| EP1689288B1 (en) | 2010-04-21 |
| EP1689288A4 (en) | 2007-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE465412T1 (de) | Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen | |
| Galvez-Sánchez et al. | Depression and trait-anxiety mediate the influence of clinical pain on health-related quality of life in fibromyalgia | |
| Sarto et al. | Effects of short‐term unloading and active recovery on human motor unit properties, neuromuscular junction transmission and transcriptomic profile | |
| Sammler et al. | Prosody meets syntax: the role of the corpus callosum | |
| Gallagher et al. | Ageing: the cholinergic hypothesis of cognitive decline | |
| Bruehl et al. | The relationship between pain sensitivity and blood pressure in normotensives | |
| Jannati et al. | Test–retest reliability of the effects of continuous theta-burst stimulation | |
| Gillivan-Murphy et al. | Voice tremor in Parkinson's disease: an acoustic study | |
| Wang et al. | 40-Hz optogenetic stimulation rescues functional synaptic plasticity after stroke | |
| Basuta et al. | High functioning male with fragile X syndrome and fragile X‐associated tremor/ataxia syndrome | |
| Ferreira‐Junior et al. | Exercise training increases GAD65 expression, restores the depressed GABAA receptor function within the PVN and reduces sympathetic modulation in hypertension | |
| Tacik et al. | Whole-exome sequencing as a diagnostic tool in a family with episodic ataxia type 1 | |
| Yavuz et al. | Maladaptive cognitive content and attitudes accompanying tension type headache and migraine | |
| GB0403490D0 (en) | Screening methods | |
| da Silva et al. | Localized APP expression results in progressive network dysfunction by disorganizing spike timing | |
| WO2007015113A3 (en) | New protein isoforms of the pif-family and uses thereof | |
| Gainotti | Measures of cognitive and emotional changes in multiple sclerosis and underlying models of brain dysfunction | |
| Kobayashi et al. | Repetitive nociceptive stimulation increases spontaneous neural activation similar to nociception-induced activity in mouse insular cortex | |
| Hayes et al. | Reassessing the lower end of the phenytoin therapeutic range: a review of the literature | |
| Safi et al. | Recruitment of the left precentral gyrus in reading epilepsy: a multimodal neuroimaging study | |
| De Las Heras et al. | Lesion location changes the association between brain excitability and motor skill acquisition post-stroke | |
| Yamamoto et al. | Characteristic features of electroencephalogram in a pediatric patient with grin1 encephalopathy | |
| Reinhart et al. | Assessing neglect dyslexia with compound words. | |
| Šulcová et al. | Evaluation of GABAAR-mediated inhibition in the human brain using TMS-evoked potentials | |
| Hamid et al. | Stigma of epilepsy among patients and their relatives attending charity clinic, Omdurman—Sudan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |